Want to see SLS full AI Analyst Report?
SELLAS Life Sciences Group (SLS) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Venetoclax, Azacitidine, Sls009 | Hematologic Malignancies | phase1AndPhase2 | Recruiting | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies | Sep 28, 2020 | ― |
| Venetoclax, Azacitidine, Cytarabine, Decitabine, Gm-Csf, Galinpepimut-S, Montanide, Observation | Acute Myeloid Leukemia | Phase III | Active Not Recruiting | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | Jan 12, 2020 | ― |
| Pembrolizumab, Gm-Csf, Galinpepimut-S, Montanide | Colorectal Cancer, Small-cell Lung Cancer, Ovarian Cancer, Acute Myelogenous Leukemia, Triple-Negative Breast Cancer | phase1AndPhase2 | Completed | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Nov 28, 2018 | ― |
| Trastuzumab, Gm-Csf, Neuvax Vaccine | Breast Cancer | Phase II | Completed | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Nov 14, 2014 | ― |
| Lenalidomide, Bortezomib, Gm-Csf, Galinpepimut-S, Montanide | Multiple Myeloma | phase1AndPhase2 | Completed | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | Apr 02, 2013 | ― |
| Herceptin, Gm-Csf, Neuvax Vaccine | Breast Cancer | Phase II | Completed | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Mar 25, 2012 | ― |
| Galinpepimut-S + Montanide + Gm-Csf, Montanide + Gm-Csf | Malignant Pleural Mesothelioma | Phase II | Completed | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | Dec 21, 2010 | ― |
| Gm-Csf, Galinpepimut-S, Montanide | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase II | Completed | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Dec 21, 2010 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Venetoclax, Azacitidine, Sls009 | phase1AndPhase2 | Hematologic Malignancies | Recruiting | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies | Sep 28, 2020 | ― |
| Venetoclax, Azacitidine, Cytarabine, Decitabine, Gm-Csf, Galinpepimut-S, Montanide, Observation | Phase III | Acute Myeloid Leukemia | Active Not Recruiting | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | Jan 12, 2020 | ― |
| Pembrolizumab, Gm-Csf, Galinpepimut-S, Montanide | phase1AndPhase2 | Colorectal Cancer, Small-cell Lung Cancer, Ovarian Cancer, Acute Myelogenous Leukemia, Triple-Negative Breast Cancer | Completed | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Nov 28, 2018 | ― |
| Trastuzumab, Gm-Csf, Neuvax Vaccine | Phase II | Breast Cancer | Completed | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Nov 14, 2014 | ― |
| Lenalidomide, Bortezomib, Gm-Csf, Galinpepimut-S, Montanide | phase1AndPhase2 | Multiple Myeloma | Completed | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | Apr 02, 2013 | ― |
| Herceptin, Gm-Csf, Neuvax Vaccine | Phase II | Breast Cancer | Completed | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Mar 25, 2012 | ― |
| Galinpepimut-S + Montanide + Gm-Csf, Montanide + Gm-Csf | Phase II | Malignant Pleural Mesothelioma | Completed | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | Dec 21, 2010 | ― |
| Gm-Csf, Galinpepimut-S, Montanide | Phase II | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Completed | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Dec 21, 2010 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Sellas Life Sciences Group (SLS) have in its pipeline
SELLAS Life Sciences Group SLS is currently developing the following drugs: Venetoclax, Azacitidine, Sls009, Venetoclax, Azacitidine, Cytarabine, Decitabine, Gm-Csf, Galinpepimut-S, Montanide, Observation, Pembrolizumab, Gm-Csf, Galinpepimut-S, Montanide, Trastuzumab, Gm-Csf, Neuvax Vaccine, Lenalidomide, Bortezomib, Gm-Csf, Galinpepimut-S, Montanide, Herceptin, Gm-Csf, Neuvax Vaccine, Galinpepimut-S + Montanide + Gm-Csf, Montanide + Gm-Csf, Gm-Csf, Galinpepimut-S, Montanide. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
